CTLA4 and melanoma: The introduction of the anti-CTLA-4 Ipilimumab in 2011 [78,79], followed by the two anti-PD-1 inhibitors, Nivolumab and Pembrolizumab in 2015 [80,81,82] for melanoma patients’ management has been revolutionary in the immune-oncology field.